5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

Pierre Fenaux, Ghulam J. Mufti, Eva Hellström‐Lindberg et al. · The Lancet Oncology · 2009 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Hagop M. Kantarjian, Xavier Thomas, Anna Dmoszyńska et al. · Journal of Clinical Oncology · 2012 · 1.2K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm

Stefan Fröhling, Richard F. Schlenk, Jochen Breitruck et al. · Blood · 2002 · 866 citations

Life Sciences, Genetics, Hematology +16

Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations

Konstanze Döhner, Richard F. Schlenk, Marianne Habdank et al. · Blood · 2005 · 845 citations · Full text

Life Sciences, Genetics, Oncology +11

Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents

Hui Yang, Carlos E. Bueso‐Ramos, Courtney DiNardo et al. · Leukemia · 2013 · 684 citations · Full text

Medicine, Hematology, Oncology +10